Aspira Women’s Health (AWHL) inks five-year Mayo Clinic lab services pact

Rhea-AI Filing Summary

Aspira Women’s Health entered into a Laboratory Services Agreement with Mayo Clinic Laboratories effective December 16, 2025. Aspira will perform its Ova1Plus (Ova1 and Overa) and OvaWatch ovarian cancer risk assessment tests for Mayo on a non-exclusive, as-requested basis for clinical use.

The initial term runs for five years with automatic one-year renewals, and either party may terminate for convenience with at least 90 days prior written notice or earlier for cause. Mayo will list the Aspira tests in its catalog, handle ordering, results delivery, and billing, while Aspira invoices Mayo at fixed fees during the initial term, subject to agreed adjustments. The agreement includes customary provisions on confidentiality, healthcare law compliance, insurance, indemnification, and non-exclusivity.

Insights

Healthcare services analyst

Aspira partners with Mayo Clinic Laboratories to provide key ovarian cancer tests under a five-year service agreement.

The agreement makes Aspira Women’s Health a reference laboratory provider to Mayo Clinic Laboratories for its Ova1Plus and OvaWatch tests, effective December 16, 2025. These tests are ordered on a non-exclusive, as-requested basis, which allows Mayo to route appropriate cases to Aspira without exclusivity constraints on either side.

The initial term is five years, followed by automatic one-year renewals, giving a potentially long-lived commercial relationship unless terminated with at least 90 days notice or for cause. Mayo will list Aspira’s tests in its catalog, manage ordering, result delivery, and billing, while Aspira invoices Mayo using fixed fees during the initial term, unless both parties agree to changes. The arrangement is framed with standard healthcare provisions on confidentiality, HIPAA compliance, insurance, indemnification, and non-exclusivity.

Aspira Women's Health Inc.0000926617false00009266172025-12-162025-12-16

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 16, 2025

ASPIRA WOMEN’S HEALTH INC.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware	​ ​ ​	001-34810	​ ​ ​	33-0595156
(State or other jurisdiction of	​	(Commission	​	(IRS Employer
incorporation or organization)	​	File Number)	​	Identification No.)

​

12117 Bee Caves Road, Building III, Suite 100

Austin, TX 78738

(Address of principal executive office) (Zip Code)

(512) 519-0400

(Registrants’ telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​	​
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​	​
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​	​
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​	​
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of each exchange on which registered
Common Stock, par value $0.001	​	AWHL	​	OTC QX Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

Item 1.01 Entry into a Material Definitive Agreement.

​

On December 16, 2025, Aspira Women’s Health Inc. (“Aspira”) entered into a Laboratory Services Agreement (the “Agreement”) with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories (“Mayo”). The Agreement is effective as of December 16, 2025. Under the Agreement, Aspira will provide certain reference laboratory testing services to Mayo, specifically the Ova1Plus (Ova1 and Overa) and OvaWatch tests, on a non-exclusive, as-requested basis for clinical purposes.

The initial term of the Agreement is five years from the effective date, with automatic one-year renewal terms thereafter, subject to earlier termination by either party for convenience on at least ninety days’ prior written notice, or earlier for cause. 

Mayo will list each Aspira test in Mayo’s catalog and will be responsible for facilitating ordering and delivery of results, as well as billing for the applicable tests. Aspira will invoice Mayo for services performed in accordance with the Agreement, with fees remaining fixed during the initial term absent mutual agreement to adjust, subject to certain notice and review rights. 

The Agreement contains customary representations, covenants, and other provisions for arrangements of this type, including with respect to confidentiality, compliance with healthcare laws (including HIPAA), insurance, indemnification, non-exclusivity, and governing law.

The Agreement is not filed herewith as Aspira is still finalizing appropriate redactions of certain information that is immaterial and the type of information that Aspira treats as private or confidential.  Aspira will file the Agreement as soon as this process is complete.

​

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: December 22, 2025

​

	ASPIRA WOMEN’S HEALTH INC.
	By:	/s/ Brian Hungerford
	Name:	Brian Hungerford
	Title:	Chief Financial Officer

​

​

​

FAQ

What agreement did Aspira Women’s Health (AWHL) enter into with Mayo Clinic Laboratories?

Aspira Women’s Health entered into a Laboratory Services Agreement with Mayo Clinic Laboratories under which Aspira provides Ova1Plus and OvaWatch reference testing services.

When did the Aspira Women’s Health and Mayo Clinic Laboratories agreement become effective?

The Laboratory Services Agreement between Aspira Women’s Health and Mayo Clinic Laboratories became effective on December 16, 2025.

What is the term of Aspira Women’s Health’s agreement with Mayo Clinic Laboratories?

The initial term is five years from the effective date, followed by automatic one-year renewal terms unless terminated earlier under the agreement.

Who handles ordering, billing, and results for Aspira’s tests under the Mayo agreement?

Mayo Clinic Laboratories will list Aspira’s tests in its catalog and will handle ordering, delivery of test results, and billing, while Aspira invoices Mayo for the services performed.

Can the Aspira–Mayo Laboratory Services Agreement be terminated early?

Yes. Either party may terminate the agreement for convenience with at least 90 days prior written notice, or earlier for cause, as specified in the agreement.

Are the Ova1Plus and OvaWatch services exclusive to Mayo Clinic Laboratories under this agreement?

No. The agreement is explicitly non-exclusive, so Aspira and Mayo are free to work with other parties for similar services.

Will Aspira Women’s Health publicly file the full Mayo Clinic Laboratories agreement?

Aspira plans to file the agreement after completing redactions of immaterial, private, or confidential information it treats as sensitive.